1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-cell malignancies
    Meeting Abstract

    Mazza, I. A.; Barba, P.; Yuda, J.; Palomba, M. L.; Alderuccio, J. P.; De Vriendt, C.; Corradini, P.; Lim, F. L. W. I.; Zinzani, P. L.; Jain, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Influence of pre-treatment features and therapy choice by physicians on overall survival in older adults with acute myeloid leukemia: A report from the beat AML master trial
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who underwent allogenic stem cell transplantation (HSCT)
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic characterization of newly diagnosed acute myeloid leukemia in patients age 60 years and older; A report from the beat AML master trial
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy vs hypomethylating agents + venetoclax (HMA/VEN) in NPM1-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study
    Meeting Abstract

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of therapy sequence on survival outcomes among patients with relapsed or refractory mature T and NK cell neoplasms: A global retrospective cohort study
    Meeting Abstract

    Sorial, M. N.; Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Eche-Ugwu, I. J.; Duan, R.; Lei, M. M.; Miranda, E.; Chiattone, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save